source
- Pfizer grants Medicus co-development rights to CD228-targeted ADC PF-08046031Pfizer announced it is transferring co-development rights for its CD228-targeted antibody-drug conjugate, PF-08046031, to Medicus Pharma. The ADC, originally discovered by Seagen, will now be adva…
- OpenEvidence introduces new family of AI models for health techOpenEvidence announced a new family of artificial intelligence models aimed at health technology applications, as reported in STAT's Health Tech newsletter. The announcement highlights the company'…